An Open-label Phase 1/2 Study to Evaluate the Safety, Biological Response and Efficacy of a Single Dose of Temferon (autologous CD34+-enriched Hematopoietic Stem and Progenitors Cells Genetically Modified with Human Interferon-α2) in Patients with Metastatic Renal Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha 2 gen e therapy-GenentaScience (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Genenta Science

Most Recent Events

09 Jan 2025 According to a Genenta Science media release, company expects to treat six patients by the end of the first half of 2025.
12 Dec 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight